Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298401 | 0.88 | HSP90AA1 (0.48) | HCAR3ALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL4394502 | 0.87 | MLYCD (0.49) | HCAR3ALDH1A1SMN1; SMN2ITGB1ITGA5 | |
| SCHEMBL9188252 | 0.86 | CASP6 (0.57) | HCAR3ALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL283683 | 0.84 | TSHR (0.62) | HCAR3ALDH1A1SMN1; SMN2HPGDTDP1 | |
| SCHEMBL6648516 | 0.83 | HCAR3 (0.54) | HCAR3ALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL3585691 | 0.83 | LMNA (0.56) | HCAR3ALDH1A1SMN1; SMN2ITGB1ITGA5 | |
| SCHEMBL5095907 | 0.83 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2ITGB1ITGA5HIF1A | |
| SCHEMBL14314759 | 0.81 | TSHR (0.62) | HCAR3ALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 | |
| SCHEMBL2249184 | 0.80 | ITGB1 (0.53) | HCAR3ALDH1A1SMN1; SMN2ITGB1ITGA5 | |
| SCHEMBL15989292 | 0.80 | HCAR3 (0.50) | HCAR3ALDH1A1SMN1; SMN2HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018699-A1 | CANNABINOID RECEPTOR SUBTYPE 2 STIMULATOR INHIBITING ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2021-02-04 | — | — | WO | disclosed |
| EP-3771713-A1 | CANNABINOID RECEPTOR SUBTYPE 2 STIMULATOR INHIBITING ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE | Julius-Maximilians-Universität Würzburg (DE) | 2021-02-03 | — | — | EP | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | COATS STEVEN J | 2010-04-15 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7652005-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| EP-1833826-B1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-7517898-B2 | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| CN-1250531-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | CN | disclosed |
| EP-1636193-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| CN-1511151-A | 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives | ֮����ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| CN-1503787-A | Novel compounds | — | 2004-06-09 | — | — | CN | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| EP-1390350-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093709-A1 | TRICYCLIC DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HCAR3 229/4885ALDH1A1 1372/4885SMN1; SMN2 3385/4885 |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | HCAR3 1793/4885ALDH1A1 1986/4885SMN1; SMN2 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.